Home
Life Sciences
Pharmaceutical
Drug Discovery and Development
Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism

Drug Discovery & Develo

Summary

Table of Contents

Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism

Publication date: September 2011

Keywords : clinical trial, drug development, clinical research, drug development process

Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism Summary GBI Research, the leading business intelligence provider, has released its latest research, “Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism”. The report provides a robust idea about patient re...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism”. The report provides a robust idea about patient recruitment status by geography, sponsor companies and year for all the major CVD indications. Furthermore, the report provides prevalence forecast data to 2017 for all the major CVD indications. The major indications covered in the report are hypertension, atrial fibrillation, dyslipidemia and venous thromboembolism. The report was built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

There has been an increase in the number of clinical trials conducted for cardiovascular diseases (CVD) due to the high prevalence of CVD. According to the American Heart Association’s (AHA) 2006 data, around 81.1 million people in the US suffer from CVD and one in every 2.9 deaths in the US is due to CVD. According to the European Heart Network’s 2008 data, CVD caused 4.3 million deaths (48%) in Europe. The high prevalence and mortality rate associated with CVD has led to an increase in research and development (R&D) activity by pharmaceutical companies.

Clinical trials are one of the most critical parts of the drug development process. The various aspects involved in clinical trials, such as the implementation of technology, efficient supply chain management, proper site selection, patient recruitment and database management among others, are crucially important. Clinical trial recruitment is a time intensive process so good strategies must be followed by pharmaceutical companies for proper patient recruitment.

Efficient patient recruitment leads to a decrease in the time and cost associated with patient recruitment. At present, the rate of new drug approvals is declining as pharmaceutical companies are under intense pressure to reduce the time required for drug development. It is equally important to cut the costs of clinical trials through proper patient recruitment. The delay in recruitment time is responsible for the increase in the timeline of clinical trial completion, the increase in costs to conduct the clinical trial and a delay in the time to market. There are many barriers to participation for the patients and for investigators who enroll the patients into the trials.

To complete the trial recruitment targets set by the sponsors or clinical research organizations (CROs), proper strategies must be planned in the initial phases of the trial. This will help to save time as well as costs in reaching the optimum patient pool for statistical analysis. If the recruitment is faster in the early stages of the trial, high and low potential sites can be identified. High-recruiting sites can then be allowed by the sponsors to exceed their targets in order to compensate for low recruiting sites.

Scope

The report analyzes the clinical trial recruitment trends of pharmaceutical companies for various cardiovascular trials. Its scope includes -
- Insight on clinical trials conducted for major indications of cardiology such as hypertension, atherosclerosis, atrial fibrillation and venous thromboembolism from 2000-2009.
- The status of patient recruitment by geography, sponsor company, year and stage of development.
- Analysis on the average number of patients recruited per trial for major indications per year.
- Analysis on the average number of patients recruited per trial for major indications by stage of development.
- The prevalence population in India, China and Brazil for all major indications from 2010-2017.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Identify and understand the status of clinical trials conducted for major cardiology indications from 2000-2009.
- Build understanding of patient recruitment status by geography, sponsor company, year and stage of development.
- Identify the prevalence population for the major indications till 2017.
- Identify the average number of patients recruited by stage of development and across years for all major indications.
- Identify the indication in which the maximum number of trials is conducted and maximum number of patients recruited.

Global Drug Discovery And Development Industry

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 9
2 Clinical Trial Recruitment in CVD - Introduction 12
2.1 GBI Research Report Guidance 13
3 Clinical Trial Recruitment in CVD - Overview 14
3.1 Clinical Trials Share by Therapeutic Area, 2005-2010 14
3.2 Clinical Trials by Major Pharmaceutical Companies, 2005-2010 21
3.3 Clinical Trial and Patient Recruitment for Major Indications, 2000-2009 22
4 Clinical Trials and Patient Recruitment for Hypertension 24
4.1 Introduction 24
4.2 Number of Clinical Trials for Hypertension 25
4.2.1 Number of Clinical Trials by Phase 25
4.2.2 Number of Clinical Trials for Hypertension by Major Sponsors 26
4.2.3 Number of Clinical Trials for Hypertension by Geography 27
4.2.4 Number of Clinical Trials for Hypertension by Year 28
4.3 Prevalence Population for Hypertension (2010-2017) 29
4.3.1 Brazil 29
4.3.2 India 30
4.3.3 China 31
4.4 Patient Recruitment for Hypertension 32
4.4.1 Number of Patients Recruited by Phase of Clinical Trial 32
4.4.2 Number of Patients Recruited by Major Sponsors 33
4.4.3 Number of Patients Recruited by Geography 34
4.4.4 Number of Patients Recruited per Year 35
4.5 Average Number of Patients Recruited Per Trial 36
4.5.1 Average Number of Patients Recruited per Trial by Stage of Development 36
4.5.2 Average Number of Patients Recruited per Trial per Year 37
5 Clinical Trials and Patient Recruitment for Atherosclerosis 38
5.1 Introduction 38
5.2 Number of Clinical Trials for Atherosclerosis 38
5.2.1 Number of Clinical Trials by Phase 38
5.2.2 Number of Clinical Trials by Sponsor 40
5.2.3 Number of Clinical Trials by Geography 41
5.2.4 Number of Clinical Trials by Year 42
5.3 Prevalence Population for Atherosclerosis (2010-2017) 43
5.3.1 Brazil 43
5.3.2 India 44
5.3.3 China 45
5.4 Patient Recruitment for Atherosclerosis 46
5.4.1 Number of Patients Recruited By Phase of Clinical Trial 46
5.4.2 Number of Patients Recruited by Sponsor 47
5.4.3 Number of Patients Recruited by Geography 48
5.4.4 Number of Patients Recruited per Year 49
5.5 Average Number of Patients Recruited per Trial 50
5.5.1 Average Number of Patients Recruited per Trial by Stage of Development 50
5.5.2 Average Number of Patients Recruited per Trial per Year 51
6 Clinical Trials and Patient Recruitment for Dyslipidemia 52
6.1 Introduction 52
6.2 Number of Clinical Trials for Dyslipidemia 52
6.2.1 Number of Clinical Trials by Phase 52
6.2.2 Number of Clinical Trials by Major Sponsor 54
6.2.3 Number of Clinical Trials by Geography 55
6.2.4 Number of Clinical Trials by Year 56
6.3 Prevalence Population for Dyslipidemia (2010-2017) 57
6.3.1 Brazil 57
6.3.2 India 58
6.3.3 China 59
6.4 Patient Recruitment for Dyslipidemia 60
6.4.1 Number of Patients Recruited by Phase of Clinical Trial 60
6.4.2 Number of Patients Recruited by Major Sponsors 61
6.4.3 Number of Patients Recruited by Geography 62
6.4.4 Number of Patients Recruited per Year 63
6.5 Average Number of Patients Recruited per Trial 64
6.5.1 Average Number of Patients Recruited per Trial by Stage of Development 64
6.5.2 Average Number of Patients Recruited per Trial per Year 65
7 Clinical Trials and Patient Recruitment for Atrial Fibrillation 66
7.1 Introduction 66
7.2 Number of Clinical Trials for Atrial Fibrillation 67
7.2.1 Number of Clinical Trials by Phase 67
7.2.2 Number of Clinical Trials by Major Sponsors 68
7.2.3 Number of Clinical Trials by Geography 69
7.2.4 Number of Clinical Trials by Year 70
7.3 Prevalence Population for Atrial Fibrillation (2010-2017) 71
7.3.1 Brazil 71
7.3.2 India 72
7.3.3 China 73
7.4 Patient Recruitment for Atrial Fibrillation 74
7.4.1 Number of Patients Recruited by Phase of Clinical Trial 74
7.4.2 Number of Patients Recruited by Major Sponsors 75
7.4.3 Number of Patients Recruited by Geography 76
7.4.4 Number of Patients Recruited per Year 77
7.5 Average Number of Patients Recruited Per Trial 78
7.5.1 Average Number of Patients Recruited per Trial by Stage of Development 78
7.5.2 Average Number of Patients Recruited per Trial per Year 79
8 Clinical Trials and Patient Recruitment for Venous Thromboembolism 80
8.1 Introduction 80
8.2 Number of Clinical Trials for Venous Thromboembolism 80
8.2.1 Number of Clinical Trials by Phase 80
8.2.2 Number of Clinical Trials by Sponsor 82
8.2.3 Number of Clinical Trials by Geography 83
8.2.4 Number of Clinical Trials by Year 84
8.3 Prevalence Population for Venous Thromboembolism (2010-2017) 85
8.3.1 Brazil 85
8.3.2 India 86
8.3.3 China 87
8.4 Patient Recruitment for Venous Thromboembolism 88
8.4.1 Number of Patients Recruited By Phase of Clinical Trial 88
8.4.2 Number of Patients Recruited by Major Sponsors 89
8.4.3 Number of Patients Recruited By Geography 90
8.4.4 Number of Patients Recruited Per Year 91
8.5 Average Number of Patients Recruited per Trial 92
8.5.1 Average Number of Patients Recruited per Trial by Stage of Development 92
8.5.2 Average Number of Patients Recruited per Trial per Year 93
9 Appendix 94
9.1 Market Definitions 94
9.2 Abbreviations 94
9.3 Research Methodology 95
9.3.1 Clinical Trials Overview 95
9.3.2 Number of Clinical Trials 95
9.3.3 Patient Recruitment Status 96
9.3.4 Prevalence of Disease in India, China and Brazil (2010-2017) 96
9.4 Coverage 96
9.5 Secondary Research 96
9.6 Primary Research 97
9.7 Expert Panel Validation 97
9.8 Contact Us 97
9.9 Disclaimer 97
9.10 Sources 98

1.1 List of Tables

Table 1: Clinical Trial Recruitment in CVD, Global, Ongoing Trials by Therapeutic Area, 2005-2010 14
Table 2: Clinical Trial Recruitment in CVD, Asia, Ongoing Trials by Therapeutic Area, 2005-2010 15
Table 3: Clinical Trial Recruitment in CVD, Europe, Ongoing Trials by Therapeutic Area, 2005-2010 16
Table 4: Clinical Trial Recruitment in CVD, Middle East, Ongoing Trials by Therapeutic Area, 2005-2010 17
Table 5: Clinical Trial Recruitment in CVD, South and Central America, Ongoing Trials by Therapeutic Area, 2005-2010 18
Table 6: Clinical Trial Recruitment in CVD, North America, Ongoing Trials by Therapeutic Area, 2005-2010 19
Table 7: Clinical Trial Recruitment in CVD, Rest of the World, Ongoing Trials by Therapeutic Area, 2005-2010 20
Table 8: Clinical Trial Recruitment in CVD, Global, Clinical Trials by Major Pharmaceutical Companies, 2005-2010 21
Table 9: Clinical Trial Recruitment in CVD, Global, Number of Clinical Trials for Major Indications, 2000-2009 22
Table 10: Clinical Trial Recruitment in CVD, Global, Number of Patients Recruited for Major Indications, 2000-2009 23
Table 11: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Clinical Trials by Phase, 2000-2009 25
Table 12: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Clinical Trials by Major Sponsors, 2000-2009 26
Table 13: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Clinical Trials by Geography, 2000 - 2009 27
Table 14: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Clinical Trials per Year, 2000 - 2009 28
Table 15: Clinical Trial Recruitment in CVD, Hypertension, Brazil, Prevalence Population, million, 2010 - 2017 29
Table 16: Clinical Trial Recruitment in CVD, Hypertension, India, Prevalence Population, million 2010 - 2017 30
Table 17: Clinical Trial Recruitment in CVD, Hypertension, China, Prevalence Population, million 2010 - 2017 31
Table 18: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Patients Recruited by Phase, 2000 - 2009 32
Table 19: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Patients Recruited by Major Sponsors, 2000 - 2009 33
Table 20: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Patients Recruited by Geography, 2000 - 2009 34
Table 21: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Patients Recruited per Year, 2000 - 2009 35
Table 22: Clinical Trial Recruitment in CVD, Hypertension, Average Number of Patients Recruited per Trial by Stage of Development, 2000 - 2009 36
Table 23: Clinical Trial Recruitment in CVD, Hypertension, Average Number of Patients Recruited per Trial per Year, 2000 - 2009 37
Table 24: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Clinical Trials, 2000 - 2009 39
Table 25: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Clinical Trials by Major Sponsors, 2000 - 2009 40
Table 26: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Clinical Trials by Geography, 2000 - 2009 41
Table 27: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Clinical Trials per Year, 2000 - 2009 42
Table 28: Clinical Trial Recruitment in CVD, Atherosclerosis, Brazil, Prevalence Population, million, 2010 - 2017 43
Table 29: Clinical Trial Recruitment in CVD, Atherosclerosis, India, Prevalence Population, million, 2010 - 2017 44
Table 30: Clinical Trial Recruitment in CVD, Atherosclerosis, China, Prevalence Population, million, 2010 - 2017 45
Table 31: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Patients Recruited by Phase, 2000 - 2009 46
Table 32: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Patients Recruited by Major Sponsors, 2000 - 2009 47
Table 33: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Patients Recruited by Geography, 2000 - 2009 48
Table 34: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Patients Recruited per Year, 2000 - 2009 49
Table 35: Clinical Trial Recruitment in CVD, Atherosclerosis, Average Number of Patients Recruited per Trial by Stage of Development, 2000 - 2009 50
Table 36: Clinical Trial Recruitment in CVD, Atherosclerosis, Average Number of Patients Recruited per Trial per Year, 2000 - 2009 51
Table 37: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Clinical Trials by Phase, 2000 - 2009 53
Table 38: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Clinical Trials by Major Sponsors, 2000 - 2009 54
Table 39: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Clinical Trials by Geography, 2000 - 2009 55
Table 40: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Clinical Trials per Year, 2000 - 2009 56
Table 41: Clinical Trial Recruitment in CVD, Dyslipidemia, Brazil, Prevalence Population, million, 2010 - 2017 57
Table 42: Clinical Trial Recruitment in CVD, Dyslipidemia, India, Prevalence Population, million, 2010 - 2017 58
Table 43: Clinical Trial Recruitment in CVD, Dyslipidemia, China, Prevalence Population, million, 2010 - 2017 59
Table 44: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Patients Recruited by Phase, 2000 - 2009 60
Table 45: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Patients Recruited by Major Sponsors, 2000 - 2009 61
Table 46: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Patients Recruited by Geography, 2000 - 2009 62
Table 47: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Patients Recruited per Year, 2000 - 2009 63
Table 48: Clinical Trial Recruitment in CVD, Dyslipidemia, Average Number of Patients Recruited per Trial by Stage of Development, 2000 - 2009 64
Table 49: Clinical Trial Recruitment in CVD, Dyslipidemia, Average Number of Patients Recruited per Trial per Year, 2000 - 2009 65
Table 50: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Clinical Trials by Phase, 2000 - 2009 67
Table 51: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Clinical Trials by Major Sponsors, 2000 - 2009 68
Table 52: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Clinical Trials by Geography, 2000 - 2009 69
Table 53: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Clinical Trials per Year, 2000 - 2009 70
Table 54: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Brazil, Prevalence Population, million, 2010 - 2017 71
Table 55: Clinical Trial Recruitment in CVD, Atrial Fibrillation, India, Prevalence Population, million, 2010 - 2017 72
Table 56: Clinical Trial Recruitment in CVD, Atrial Fibrillation, China, Prevalence Population, million, 2010 - 2017 73
Table 57: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Patients Recruited by Phase, 2000 - 2009 74
Table 58: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Patients Recruited by Major Sponsors, 2000 - 2009 75
Table 59: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Patients Recruited by Geography, 2000 - 2009 76
Table 60: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Patients Recruited per Year, 2000 - 2009 77
Table 61: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Average Number of Patients Recruited per Trial by Stage of Development, 2000 - 2009 78
Table 62: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Average Number of Patients Recruited per Trial per Year, 2000 - 2009 79
Table 63: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Clinical Trials by Phase, 2000 - 2009 81
Table 64: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Clinical Trials by Major Sponsors, 2000 - 2009 82
Table 65: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Clinical Trials by Geography, 2000 - 2009 83
Table 66: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Clinical Trials per Year, 2000 - 2009 84
Table 67: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Brazil, Prevalence Population, thousands, 2010 - 2017 85
Table 68: Clinical Trial Recruitment in CVD, Venous Thromboembolism, India, Prevalence Population, million, 2010 - 2017 86
Table 69: Clinical Trial Recruitment in CVD, Venous Thromboembolism, China, Prevalence Population, million, 2010 - 2017 87
Table 70: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Patients Recruited by Phase, 2000 - 2009 88
Table 71: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Patients Recruited by Major Sponsors, 2000 - 2009 89
Table 72: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Patients Recruited by Geography, 2000 - 2009 90
Table 73: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Patients Recruited per Year, 2000 - 2009 91
Table 74: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Average Number of Patients Recruited per Trial by Stage of Development, 2000 - 2009 92
Table 75: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Average Number of Patients Recruited per Trial per Year, 2000 - 2009 93

1.2 List of Figures

Figure 1: Clinical Trial Recruitment in CVD, Global, Ongoing Trials by Therapeutic Area, 2005-2010 14
Figure 2: Clinical Trial Recruitment in CVD, Asia, Ongoing Trials by Therapeutic Area, 2005-2010 15
Figure 3: Clinical Trial Recruitment in CVD, Europe, Ongoing Trials by Therapeutic Area, 2005-2010 16
Figure 4: Clinical Trial Recruitment in CVD, Middle East, Ongoing Trials by Therapeutic Area, 2005-2010 17
Figure 5: Clinical Trial Recruitment in CVD, South and Central America, Ongoing Trials by Therapeutic Area, 2005-2010 18
Figure 6: Clinical Trial Recruitment in CVD, North America, Ongoing Trials by Therapeutic Area, 2005-2010 19
Figure 7: Clinical Trial Recruitment in CVD, Rest of the World, Ongoing Trials by Therapeutic Area, 2005-2010 20
Figure 8: Clinical Trial Recruitment in CVD, Global, Clinical Trials by Major Pharmaceutical Companies, 2005-2010 21
Figure 9: Clinical Trial Recruitment in CVD, Global, Number of Clinical Trials for Major Indications, 2000-2009 22
Figure 10: Clinical Trial Recruitment in CVD, Global, Number of Patients Recruited for Major Indications, 2000-2009 23
Figure 11: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Clinical Trials by Phase, 2000 - 2009 25
Figure 12: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Clinical Trials by Major Sponsors, 2000 - 2009 26
Figure 13: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Clinical Trials by Geography, 2000 - 2009 27
Figure 14: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Clinical Trials per Year, 2000 - 2009 28
Figure 15: Clinical Trial Recruitment in CVD, Hypertension, Brazil, Prevalence Population, million, 2010 - 2017 29
Figure 16: Clinical Trial Recruitment in CVD, Hypertension, India, Prevalence Population, million 2010 - 2017 30
Figure 17: Clinical Trial Recruitment in CVD, Hypertension, China, Prevalence Population, million 2010 - 2017 31
Figure 18: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Patients Recruited by Phase, 2000 - 2009 32
Figure 19: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Patients Recruited by Major Sponsors, 2000 - 2009 33
Figure 20: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Patients Recruited by Geography, 2000 - 2009 34
Figure 21: Clinical Trial Recruitment in CVD, Hypertension, Total Number of Patients Recruited per Year, 2000 - 2009 35
Figure 22: Clinical Trial Recruitment in CVD, Hypertension, Average Number of Patients Recruited per Trial by Stage of Development, 2000 - 2009 36
Figure 23: Clinical Trial Recruitment in CVD, Hypertension, Average Number of Patients Recruited per Trial per Year, 2000 - 2009 37
Figure 24: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Clinical Trials, 2000 - 2009 38
Figure 25: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Clinical Trials by Major Sponsors, 2000 - 2009 40
Figure 26: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Clinical Trials by Geography, 2000 - 2009 41
Figure 27: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Clinical Trials per Year, 2000 - 2009 42
Figure 28: Clinical Trial Recruitment in CVD, Atherosclerosis, Brazil, Prevalence Population, million, 2010 - 2017 43
Figure 29: Clinical Trial Recruitment in CVD, Atherosclerosis, India, Prevalence Population, million, 2010 - 2017 44
Figure 30: Clinical Trial Recruitment in CVD, Atherosclerosis, China, Prevalence Population, million, 2010 - 2017 45
Figure 31: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Patients Recruited by Phase, 2000 - 2009 46
Figure 32: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Patients Recruited by Major Sponsors, 2000 - 2009 47
Figure 33: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Patients Recruited by Geography, 2000 - 2009 48
Figure 34: Clinical Trial Recruitment in CVD, Atherosclerosis, Total Number of Patients Recruited per Year, 2000 - 2009 49
Figure 35: Clinical Trial Recruitment in CVD, Atherosclerosis, Average Number of Patients Recruited per Trial by Stage of Development, 2000 - 2009 50
Figure 36: Clinical Trial Recruitment in CVD, Atherosclerosis, Average Number of Patients Recruited per Trial per Year, 2000 - 2009 51
Figure 37: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Clinical Trials by Phase, 2000 - 2009 52
Figure 38: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Clinical Trials by Major Sponsors, 2000 - 2009 54
Figure 39: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Clinical Trials by Geography, 2000 - 2009 55
Figure 40: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Clinical Trials per Year, 2000 - 2009 56
Figure 41: Clinical Trial Recruitment in CVD, Dyslipidemia, Brazil, Prevalence Population, million, 2010 - 2017 57
Figure 42: Clinical Trial Recruitment in CVD, Dyslipidemia, India, Prevalence Population, million, 2010 - 2017 58
Figure 43: Clinical Trial Recruitment in CVD, Dyslipidemia, China, Prevalence Population, million, 2010 - 2017 59
Figure 44: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Patients Recruited by Phase, 2000 - 2009 60
Figure 45: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Patients Recruited by Major Sponsors, 2000 - 2009 61
Figure 46: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Patients Recruited by Geography, 2000 - 2009 62
Figure 47: Clinical Trial Recruitment in CVD, Dyslipidemia, Total Number of Patients Recruited per Year, 2000 - 2009 63
Figure 48: Clinical Trial Recruitment in CVD, Dyslipidemia, Average Number of Patients Recruited per Trial by Stage of Development, 2000 - 2009 64
Figure 49: Clinical Trial Recruitment in CVD, Dyslipidemia, Average Number of Patients Recruited per Trial per Year, 2000 - 2009 65
Figure 50: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Clinical Trials by Phase, 2000 - 2009 67
Figure 51: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Clinical Trials by Major Sponsors, 2000 - 2009 68
Figure 52: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Clinical Trials by Geography, 2000 - 2009 69
Figure 53: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Clinical Trials per Year, 2000 - 2009 70
Figure 54: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Brazil, Prevalence Population, million, 2010 - 2017 71
Figure 55: Clinical Trial Recruitment in CVD, Atrial Fibrillation, India, Prevalence Population, million, 2010 - 2017 72
Figure 56: Clinical Trial Recruitment in CVD, Atrial Fibrillation, China, Prevalence Population, million, 2010 - 2017 73
Figure 57: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Patients Recruited by Phase, 2000 - 2009 74
Figure 58: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Patients Recruited by Major Sponsors, 2000 - 2009 75
Figure 59: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Patients Recruited by Geography, 2000 - 2009 76
Figure 60: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Total Number of Patients Recruited per Year, 2000 - 2009 77
Figure 61: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Average Number of Patients Recruited per Trial by Stage of Development, 2000 - 2009 78
Figure 62: Clinical Trial Recruitment in CVD, Atrial Fibrillation, Average Number of Patients Recruited per Trial per Year, 2000 - 2009 79
Figure 63: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Clinical Trials by Phase, 2000 - 2009 80
Figure 64: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Clinical Trials by Major Sponsors, 2000 - 2009 82
Figure 65: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Clinical Trials by Geography, 2000 - 2009 83
Figure 66: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Clinical Trials per Year, 2000 - 2009 84
Figure 67: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Brazil, Prevalence Population, thousands, 2010 - 2017 85
Figure 68: Clinical Trial Recruitment in CVD, Venous Thromboembolism, India, Prevalence Population, million, 2010 - 2017 86
Figure 69: Clinical Trial Recruitment in CVD, Venous Thromboembolism, China, Prevalence Population, million, 2010 - 2017 87
Figure 70: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Patients Recruited by Phase, 2000 - 2009 88
Figure 71: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Patients Recruited by Major Sponsors, 2000 - 2009 89
Figure 72: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Patients Recruited by Geography, 2000 - 2009 90
Figure 73: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Total Number of Patients Recruited per Year, 2000 - 2009 91
Figure 74: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Average Number of Patients Recruited per Trial by Stage of Development, 2000 - 2009 92
Figure 75: Clinical Trial Recruitment in CVD, Venous Thromboembolism, Average Number of Patients Recruited per Trial per Year, 2000 - 2009 93

Companies Mentioned

Talk to Robyn

(866) 682 9815

Send Your Request

Follow

Add to circles Subscribe to our RSS feeds!

Global Drug Discovery And Development Industry : Latest Reports

The Americas Pharmaceutical & Healthcare Reports

$ 9 048
Industry report
February 2013
by Business Monitor International

Espicom market intelligence, brought to you by Business Monitor International The Americas Pharmaceuticals & Healthcare Reports feature independent forecasts for drugs and healthcare expenditure and imports ...

Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery

$ 5 450
Industry report
March 2013
by BCC Research

REPORT SCOPE INTRODUCTION STUDY GOALS AND OBJECTIVES This BCC Research report, Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery, provides an overview of the ...

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech

$ 4 995
Industry report
May 2013
by Currentpartnering

The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and ...

Global Ion Channel Modulators Industry

March 2013 $ 4 500

Biologicals In Oncology Drug Pipeline Upda ...

April 2013 $ 3 749

Discovery Stage Partnering Terms And Agree ...

May 2013 $ 2 995

Bioinformatics Partnering Terms And Agreem ...

March 2013 $ 2 795

Abdominal Aortic Aneurysms Global Clinical ...

January 2013 $ 2 500

Hemostasis Global Clinical Trials Review, ...

January 2013 $ 2 500

Portal Hypertension Global Clinical Trials ...

January 2013 $ 2 500

More Reports:

Drug Discovery and Development in China (12)

Drug Discovery and Devel... in India (11)

Drug Discovery and Develo... in Japan (5)

Drug Discov... in the United States (165)

Company Reports

Novartis Inc.

GlaxoSmithKline P.L.C.

Pfizer Inc.

GlaxoSmithKline PLC

Johnson And Johnson

AstraZeneca PLC

Astellas Pharma Inc.

Bayer AG

Imperial College Of Science

Ottawa Hospital

Global Drug Discovery And Development Industry : Latest Downloads

Clinical Research : Innovation and Technology Trends

Industry report
May 2013
2 pages

... Services. Contact him at 1.650.465.0119 Or figure 1. Supply and demand for clinical research personnel (2012/2013) ...

Clinical Trial : Innovation and Technology Trends

Industry report
March 2013
17 pages

... By activities: - demand planning - clinical trial supply set-up (packaging design, label approval, etc.) - Inventory management - ivr set-up - outsourcing - logistics increasing trend in cts is to take ...

The Future of Clinical Trial

Industry report
January 2013
9 pages

Related Market Segments :

Clinical Trial

Drug Development

Country Reports

World

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.